Welcome to our dedicated page for Innoviva news (Ticker: INVA), a resource for investors and traders seeking the latest updates and insights on Innoviva stock.
Innoviva, Inc. reports developments across a diversified biopharmaceutical business built around a core royalty portfolio, Innoviva Specialty Therapeutics, and strategic healthcare investments. Recurring updates cover royalty revenue from GSK-related respiratory products, IST commercial performance in critical care and infectious disease medicines, and capital allocation actions such as share repurchases.
Company news also includes regulatory and clinical developments for IST antibiotics, including NUZOLVENCE (zoliflodacin) for uncomplicated urogenital gonorrhea, ZEVTERA updates, medical-conference presentations, and changes in the value of strategic healthcare assets such as Armata Pharmaceuticals investments.
Innoviva reported third quarter 2024 financial results, highlighting strong performance and significant progress. Key points include:
Royalty revenue: $60.5 million from GSK, a 6% year-over-year increase.
Net product sales: $27.8 million, with U.S. sales at $19.7 million, reflecting a 68% growth. GIAPREZA® contributed $13.1 million, XERAVA® $2.3 million, and XACDURO® $4.3 million.
License revenue: $4.6 million from development cost-sharing reimbursements.
Net income: $1.2 million, or $0.02 per share, down from $82.0 million, or $1.26 per share in Q3 2023.
Cash and assets: $260.6 million in cash and equivalents, with $91.1 million in receivables.
Notable achievements include the nomination of XACDURO® for the 2024 Prix Galien USA Award and plans to submit an NDA for zoliflodacin in early 2025.
Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 10:30 a.m. Eastern Time. Additionally, Innoviva will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, at 3:40 p.m. Eastern Time.
Both presentations will be accessible via live webcasts in the Investor Relations section of Innoviva's website. Archived replays will also be available after the events. This participation demonstrates Innoviva's commitment to engaging with investors and showcasing its portfolio, which includes a core royalties segment and a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST).
Innoviva (NASDAQ: INVA) reported strong Q2 2024 financial results, showcasing growth across multiple fronts. Key highlights include:
- GSK royalties of $67.2 million, up from $65.7 million in Q2 2023
- Net product sales of $21.7 million, a 38% year-over-year increase
- License revenue of $14.5 million, including an $8 million milestone payment for XACDURO® approval in China
- Net loss of $34.7 million, primarily due to unfavorable changes in investment fair values
- Completed $100 million share repurchase program
The company's core products, XACDURO® and XERAVA®, received recognition in important treatment guidelines. Innoviva remains focused on enhancing shareholder value through capital allocation and operational excellence.
Innoviva (Nasdaq: INVA), a diversified holding company with a core royalties portfolio and a strong presence in critical care and infectious disease through Innoviva Specialty Therapeutics (IST), announced that its CEO, Pavel Raifeld, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place in Miami, FL on June 10, 2024, at 1:20 p.m. Eastern Time. The session will be available via live webcast on the company's Investor Relations webpage and can be replayed for 90 days.
Innoviva, Inc. (NASDAQ: INVA) reported strong first quarter financial results with $61.9 million in GSK royalties, $19.1 million in net product revenues, and a successful pipeline. The company highlighted positive Phase 3 zoliflodacin clinical trial results and key appointments.
Innoviva, Inc. (NASDAQ: INVA) will participate in the BofA Securities Health Care Conference. The company, a holding firm with a core royalties portfolio and a strong presence in critical care and infectious disease treatment, will have its CEO, Pavel Raifeld, present at the conference on May 15, 2024. Interested parties can access a live webcast of the event on the company's Investor Relations website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.